{"filing":{"accession_number":"0001213900-26-073735","cik":"0001941029","ticker":"ADVB","company_name":"Advanced Biomed Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"ea0296529-8k_advanced.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1941029/000121390026073735/ea0296529-8k_advanced.htm"},"events":[{"id":15101,"run_id":13469,"accession_number":"0001213900-26-073735","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Advanced Biomed Inc. entered into a Share Purchase Agreement to sell 100% of its Taiwan Subsidiary for US$490,000. This is a material disposition of a wholly-owned subsidiary that conducts the Company's biomedical R\u0026D operations, including the A+PerfusC platform. The transaction represents a significant change in the Company's operational structure and asset base, qualifying as material M\u0026A activity under Item 1.01.","company_name":"Advanced Biomed Inc.","ticker":"ADVB","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12738,"accession_number":"0001213900-26-073735","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Advanced Biomed Inc. entered into a Share Purchase Agreement to sell 100% of its Taiwan Subsidiary for US$490,000. This is a material disposition of a wholly-owned subsidiary that conducts the Company's biomedical R\u0026D operations, including the A+PerfusC platform. The transaction represents a significant change in the Company's operational structure and asset base, qualifying as material M\u0026A activity under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:25:55.081032+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12738,"accession_number":"0001213900-26-073735","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Advanced Biomed Inc. entered into a Share Purchase Agreement to sell 100% of its Taiwan Subsidiary for US$490,000. This is a material disposition of a wholly-owned subsidiary that conducts the Company's biomedical R\u0026D operations, including the A+PerfusC platform. The transaction represents a significant change in the Company's operational structure and asset base, qualifying as material M\u0026A activity under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:25:55.081032+00:00","company_name":"Advanced Biomed Inc.","ticker":"ADVB","filing_date":"2026-06-30"}]}